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For over half a century, clinicians and researchers have endeavored to 
understand the relationship between oxygen delivery and lactic acidosis (1,2). 
Or, as discussed later, perhaps more readily considered as “hyperlactatemia with 
or without acidemia”. In health, pyruvate (the generally-acknowledged end-
product of glycolysis) is metabolized by mitochondria to acetyl CoA to feed the 
tricarboxylic acid cycle.  Excess pyruvate is reduced by lactate dehydrogenase to 
L-lactate. Notably, this reduction consumes a proton: pyruvate + NADH + H+ ←→ 
lactate + NAD+. Lactate is subsequently oxidized back to pyruvate, either locally 
or after transfer to organs that utilise lactate as a fuel source (e.g. liver, kidney, 
brain), or that convert it back to glucose (Cori cycle in the liver). In concert, these 
processes maintain normal blood lactate levels.  
During sepsis, lactate levels frequently rise.  Indeed, hyperlactatemia (a 
measurable surrogate for cellular/metabolic perturbations) is closely associated 
with sepsis prognosis and is now one of the criteria for septic shock (3). 
However, it remains challenging to determine clinically when a persistently 
elevated serum lactate level indicates ongoing inadequacy of oxygen delivery, or 
when the problem lies elsewhere.  The brainstem response to give yet more fluid 
is often inappropriate and potentially injurious.
Hyperlactatemia during sepsis may result from anaerobic glycolysis.  When 
whole-body oxygen delivery fails to meet cellular demands, tissues transition from 
mitochondrial aerobic respiration to less efficient ATP generation by glycolysis.  
This is most common at the time of initial patient presentation and, in many cases, 
resolves with administration of intravenous fluids ± vasoactive agents.  However, 
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other factors may also increase serum lactate levels in sepsis, including β2-
receptor stimulation from endogenous/exogenous catecholamines, impaired tissue 
oxygen extraction (mitochondrial ± microcirculatory dysfunction), liver dysfunction, 
and thiamine deficiency.
To aid the clinician in his/her decision-making, Gattinoni and colleagues in 
this issue of the Journal propose a conceptual model relating oxygen delivery and 
utilization, serum lactate concentration, and acidemia (4). They analyzed data from 
1741 intensive care unit (ICU) patients enrolled into the Albumin Italian Outcome 
Sepsis (ALBIOS) trial using serum lactate, central venous oxygen saturation 
(ScvO2) and blood gas measurements taken at study enrollment (5).  
Fundamentally, their proposed model frames two clinical questions:
1.  Is an elevated lactate level due to inadequate oxygen delivery, and 
therefore potentially responsive to interventions that increase oxygen 
delivery?
2.  How does an elevated serum lactate affect arterial pH and base 
excess?
Hyperlactatemia and central venous oxygen saturation
High values of ScvO2 suggest either a systemic oxygen delivery in excess 
of oxygen demand, impaired cellular (mitochondrial) oxygen utilization, and/or 
microcirculatory shunting.  Low ScvO2 values imply inadequate oxygen delivery 
that fails to meet metabolic demands. Gattinoni and colleagues propose using 
ScvO2 to personalize sepsis management, reserving interventions to increase 
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oxygen delivery only to those patients with low ScvO2 values. Of note, only 35% 
of patients in the ALBIOS trial had ScvO2 values <70%. Other recent sepsis trials 
report similar ScvO2 values after initial resuscitation (6).
This proposal is not inherently novel.  The concept of early goal-directed 
therapy (EGDT) (7) and the Surviving Sepsis Campaign recommendations (8) 
both suggest a low ScvO2 should trigger interventions to increase oxygen 
delivery (e.g. fluid, inotropes, blood). This concept has a strong physiologic 
rationale, but the devil is in the detail.  
First, the patients in ALBIOS study and the three recent EGDT trials (6) 
were all enrolled after initial resuscitation. On first presentation, many will have 
impaired oxygen delivery and thus lower ScvO2 values, and a higher likelihood of 
responding positively to empiric fluid administration. An important caveat is that a 
low ScvO2 in sepsis does not automatically equate to hypovolemia. 
Cardiomyopathy can also contribute, and may be worsened by excessive fluid 
administration.
Second, many patients with sepsis-associated hyperlactatemia have 
ScvO2 values falling within an indeterminate range; even patients with an 
elevated ScvO2 may respond physiologically to fluid administration (9). Moreover, 
ScvO2 is a ‘global’ (or, rather an ‘upper-body’) measure of oxygen supply-
demand balance, and may miss imbalances in specific tissue beds (10). 
Finally, the history of sepsis research is paved with physiologically-rational 
interventions that nonetheless failed to improve patient outcomes (11). The 
recent EGDT trials showed no benefit in targeting ScvO2 even among the subset 
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of patients with baseline values <70% (6).  Interventions to increase oxygen 
delivery may carry unintended consequences outside the mechanistic pathway 
assessed by ScvO2 measurement (12,13). Therefore, an ScvO2-based strategy 
to personalize interventions for patients with sepsis-associated hyperlactatemia 
requires careful evaluation in clinical trials before any recommendation of 
standard-of-care implementation in clinical practice. 
Hyperlactatemia and arterial pH
Applying strong ion theory, lactate is a strong anion and should thus be 
completely dissociated from hydrogen in plasma, generating an acidosis. 
However, some sepsis patients with hyperlactatemia have a concurrently 
decreased pH (acidemia) whereas others maintain a normal pH. This suggests 
mechanisms that enable relatively rapid respiratory or metabolic compensation. 
Gattinoni and colleagues found that the ability to maintain a normal pH despite 
elevated lactate was more closely correlated with renal function than respiratory 
compensation. They propose using an indirect measure of the accumulation of 
renally-excreted fixed acids in plasma - the “alactic base excess” – to assess the 
kidneys’ ability to compensate for acid-base disturbances.
Standard base excess, defined as the amount of strong acid that must be 
added to each liter of oxygenated blood to return the pH to 7.40 at a PaCO2 of 40 
mmHg, quantifies the degree of metabolic acidosis or alkalosis independently of 
respiratory compensation.  Contributors to base excess include lactate, strong 
ions such as sodium and chloride, albumin, and ions that accumulate in renal 
Page 5 of 9  AJRCCM Articles in Press. Published on 19-May-2019 as 10.1164/rccm.201904-0899ED 
 Copyright © 2019 by the American Thoracic Society 
failure such as phosphate and sulfate (14).  By adding lactate to standard base 
excess, the authors arrive at the alactic base excess which they assert quantifies 
“the role of renal function on acid-base balance in sepsis.”  
 This suggestion is certainly interesting but requires further thought and 
investigation.  Renal compensation for acid-base disturbances has traditionally 
been considered to be slower than respiratory compensation. Detailed data on 
urine output, stage of acute kidney injury (15), minute ventilation, and other 
physiologic measures would be required before the relative causal effects of 
kidney injury in compensating for an acidosis could be fully understood.  Alactic 
base excess is not necessarily an explicit measure of renal function.  For 
example, administration of 0.9% sodium chloride decreases base excess, even 
in the presence of stable renal function and lactate concentrations (16).  The 
impact of concurrent liver dysfunction requires consideration; few such patients 
were in the ALBIOS database. Nonetheless, the concept of alactic base excess 
and the role of renal function in modifying acidemia warrant evaluation in future 
physiologic studies.
In summary, Gattinoni and colleagues are to be congratulated for 
advancing an ambitious conceptual model relating oxygen delivery, lactate 
generation, renal function, and acidemia in sepsis.  We are eager to see future 
research to confirm and refine this model – and move us closer to the authors’ 
vision of a more personalized approach to early hemodynamic management for 
sepsis.
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